Drug Information

Drug General Information
Drug ID
D0J1TS
Former ID
DCL000462
Drug Name
AZD2207
Drug Type
Small molecular drug
Indication Diabetes; Obesity [ICD9: 250, 278; ICD10:E08-E13, E66] Discontinued in Phase 2 [548462]
Company
AstraZeneca
Structure
Download
2D MOL

3D MOL
Formula
C22H22Cl2F2N4O3+2
Canonical SMILES
CC(C1=CC(=CC=C1)Cl)NC(=O)CC2=C(C=CC(=[N+]2O)NCC(C3=CC=C<br />C=[N+]3O)(F)F)Cl
InChI
1S/C22H20Cl2F2N4O3/c1-14(15-5-4-6-16(23)11-15)28-21(31)12-18-17(24)8-9-20(30(18)33)27-13-22(25,26)19-7-2-3-10-29(19)32/h2-11,14,33H,12-13H2,1H3,(H-,28,31,32)/p+2/t14-/m1/s1
InChIKey
GNYWBETUYIZBHL-CQSZACIVSA-P
PubChem Compound ID
6398473
PubChem Substance ID
7888583, 42999810, 52864344, 114510531, 134339070, 134340158
Target and Pathway
Target(s) Cannabinoid receptor 1 Target Info Antagonist [550288], [551589]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
PANTHER Pathway Endogenous cannabinoid signaling
Pathway Interaction Database N-cadherin signaling events
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
BDNF signaling pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 548462Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025707)
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).
Ref 551589Ghrelin agonist TZP-101/ulimorelin accelerates gastrointestinal recovery independently of opioid use and surgery type: covariate analysis of phase 2 data. World J Surg. 2012 Jan;36(1):39-45.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.